No single tool does everything, and pretending otherwise just creates friction for the people doing the work. Bioinformaticians live in a mixed ecosystem (a bit of Python here, an R package there, a platform for the heavy lifting), and the tools that respect that reality are the ones that actually get used. This release is about interoperability: meeting your data where it already is.
If you've already done QC, normalization, and clustering in Scanpy, there's no reason to redo it. Rosalind now imports Scanpy-processed single-cell datasets directly from .h5ad files, so completed work comes along and you move straight into exploration, annotation, and comparison. And when you need to keep going outside Rosalind, you can export filtered .h5ad files back out. Data in, data out, no lock-in.
Gene List Manager now lets you share gene lists across your entire group, so collaborators work from the same curated gene sets across experiments and meta-analyses. A new overview panel shows each list's details, permissions, and usage in one place. And a quiet-but-important fix: gene-name casing inconsistencies no longer silently break meta-analyses: the kind of bug that erodes trust precisely because it fails without saying so.
Target Explorer has been rebuilt from the inside out, with cleaner navigation, clearer permissions, and better performance, making it faster to get to the surface-marker insights teams rely on, with consistent access managed through subscription settings.
Open, interoperable workflows aren't a nice-to-have anymore; they're an expectation. The best outcome is when Rosalind is simply the most powerful stop in a workflow you already trust, not a walled garden you have to commit to. There's a bigger reason we care so much about getting data in cleanly, too: every dataset brought into one rigorous, well-harmonized home makes the whole more valuable than the sum of its parts. The more of your science that lives in one consistent place, the more the platform can eventually reason across it. That's the direction we're building.